TMX group

TORONTO, Aug. 1 /CNW/ - NeuroMedix Inc. ("NeuroMedix") (TSXV: NMX) today
announced that its Annual Meeting of Shareholders will be held at the MaRS
Discovery District, MaRS Centre, South Tower, 101 College Street, Ground
Floor, Room CR-2, Toronto, Ontario, on Thursday, August 3, 2006 at 4:30 p.m.
(Toronto time).
The Chief Executive Officer of NeuroMedix, Dr. Mark Pearson, will review
NeuroMedix's achievements since its initial public offering in January 2006,
as well as present plans for the current year.
Following the Annual Meeting of Shareholder's, Dr. Pearson's presentation
will be available on NeuroMedix's web site at www.neuromedixinc.com.

About NeuroMedix:

NeuroMedix is a biotechnology company focused on the development of
therapeutic agents for the treatment of degenerative and inflammatory diseases
of the central nervous system, such as Alzheimer's disease, traumatic brain
injury, neuropathic pain, age-related macular degeneration and multiple
sclerosis. Our therapeutic drug candidates are based on research from a team
of leading experts in the field of neuroinflammation at Northwestern
University and have been demonstrated to reduce brain inflammation, to protect
neuronal cells, and to prevent the loss of cognitive function in an
Alzheimer's disease animal model in mice. Our lead candidate, Minozac has also
been shown to reduce inflammation and prevent loss of cognitive function in
mice suffering traumatic brain injury. Based on these findings, NeuroMedix is
pursuing the development of its lead compound for Alzheimer's disease and
traumatic brain injury in humans. NeuroMedix's shares are listed on the TSX
Venture Exchange under the symbol "NMX".

The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.

Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risks and
uncertainties, which may include but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

%SEDAR: 00022976E